source
- New antibody-drug conjugates show promise as potential standard for extensive-stage small cell lung cancer at WCLC 2026The World Conference on Lung Cancer showcased several late‑stage trial updates, with a focus on new therapies for small cell lung cancer, the more aggressive form of the disease. Antibody‑drug con…
- GSK to acquire Chimagen’s trispecific T-cell engager program in deal up to $750 millionGSK announced it will acquire a preclinical trispecific T cell engager program from Chinese biotech Chimagen Biosciences in a transaction that could total up to $750 million. The agreement provide…